ZTS Stock Price Today (October 2026) — Zoetis Inc. Analysis & Key Metrics 2026-10-07
Zoetis Inc. (ZTS) is trading at $71.55, up 0.31% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $96.00 (34.2% upside).
- Volatility is low (19.37% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-0.20% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
ZTS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Zoetis Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $37.15B
P/E Ratio
Forward P/E: 11.80
Revenue Growth
Year over Year
Analyst Target
+34.2% upside potential
Key Investor Questions About ZTS
What investors need to know before buying
Based on current market data, ZTS presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 49.52)
- Fundamentals say: Challenging (declining revenue trends)
ZTS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ZTS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $9.26B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, ZTS stock traded between $68.92 and $148.79 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.37% annualized volatility and β=0.63, the stock exhibits low sensitivity to market moves—making ZTS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
Zoetis (ZTS) Stock Fair Value Falls After Mixed Analyst Cuts And Softer Growth Views
Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri
Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS
Michael Burry says Lululemon’s valuation has become increasingly attractive and sees Zoetis as “very cheap” despite the risk of further downside.
1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges
Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investor’s dilemma: bargain opportunity or value trap?
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.
Zoetis (ZTS) Shares Drop After Earnings Revision
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the “Impax US Sustainable Economy Fund”. The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at […]
Is Zoetis Stock Underperforming the S&P 500?
Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.
Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.
Explore More Analysis for ZTS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Zoetis Inc.
Zoetis Inc. (ZTS) is currently trading at $71.55. The RSI (14-day) is at 49.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $96.00 implies 34.2% upside from current levels. Volatility is low at 19.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Zoetis Inc. (ZTS): The trailing P/E ratio is 12.06, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 11.80, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 6.72, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 9.40. Price-to-Sales is 3.20. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering ZTS, the consensus price target is $96.00. This represents a 34.2% upside from the current price of $71.55. The range spans from a low target of $80.00 to a high target of $155.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Zoetis Inc. (ZTS) pays a dividend with a current yield of approximately 2.96%. The annualized dividend rate is $2.06 per share. The payout ratio is 33.6%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Jul 20, 2026.
Key risks for Zoetis Inc. (ZTS) investors include: 1. Elevated debt levels (debt-to-equity of 2.94x) which could pressure margins in a rising rate environment. 2. Declining revenue (-0.2% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Zoetis Inc.'s (ZTS) current debt and financial health profile: Total debt stands at $9.26B. The debt-to-equity ratio is 2.94x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.08, indicating strong short-term liquidity. The quick ratio is 1.58. The company holds $1.68B in cash and equivalents. Free cash flow is positive at $2.02B, providing a cushion for debt servicing and shareholder returns.